Epistem CEO: Indian TB deal first among many for Genedrive
This article was originally published in Clinica
Executive Summary
Epistem last week announced a partnership with biotech firm Xcelris Laboratories to evaluate the Genedrive system – the UK company's point-of-need molecular diagnostics platform – for the early detection of tuberculosis (TB) in India. However, this deal is just the tip of the iceberg. Having spent four to five years developing the technology, Epistem has dedicated the last six months to ramping up production of the handheld analysers and building up the assay processes to support other deals – similar to the one it has with Xcelris – which it has lined up for Genedrive, according to Epistem CEO Matthew Walls.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.